Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates

(2016) Jeffrey C. Kern et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Recent advances in the construction of antibody–drug conjugates

(2016) Vijay Chudasama et al.   Nature Chemistry

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

(2015) Jessica R. McCombs et al.   AAPS Journal

Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody–Drug Conjugates

(2015) Remon van Geel et al.   BIOCONJUGATE CHEMISTRY

Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody–Drug Conjugates Using Click Cycloaddition Chemistry

(2015) Michael P. VanBrunt et al.   BIOCONJUGATE CHEMISTRY

An emerging playbook for antibody–drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety

(2015) Penelope M Drake et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

(2015) Christopher R. Behrens et al.   MOLECULAR PHARMACEUTICS

Metabolites of Antibody–Maytansinoid Conjugates: Characteristics and in Vitro Potencies

(2015) Wayne Widdison et al.   MOLECULAR PHARMACEUTICS

In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios

(2015) Penny Bryant et al.   MOLECULAR PHARMACEUTICS

Organometallic palladium reagents for cysteine bioconjugation

(2015) Ekaterina V. Vinogradova et al.   NATURE

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Evolving Strategies for Target Selection for Antibody-Drug Conjugates

(2015) Marc Damelin et al.   PHARMACEUTICAL RESEARCH

Current ADC Linker Chemistry

(2015) Nareshkumar Jain et al.   PHARMACEUTICAL RESEARCH

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy

(2015) Antoine Maruani et al.   Nature Communications

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency

(2015) Roger R. Beerli et al.   PLoS One

Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

(2014) Ravi V. J. Chari et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Regioselective and Stoichiometrically Controlled Conjugation of Photodynamic Sensitizers to a HER2 Targeting Antibody Fragment

(2014) Francesca Bryden et al.   BIOCONJUGATE CHEMISTRY

Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates

(2014) Patrick Dennler et al.   BIOCONJUGATE CHEMISTRY

Production of Site-Specific Antibody–Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System

(2014) Erik S. Zimmerman et al.   BIOCONJUGATE CHEMISTRY

Site-Specific Antibody–Drug Conjugation through Glycoengineering

(2014) Qun Zhou et al.   BIOCONJUGATE CHEMISTRY

Antibody–drug conjugates—A new wave of cancer drugs

(2014) Hervé Bouchard et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A general approach to site-specific antibody drug conjugates

(2014) Feng Tian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates

(2013) Pavel Strop et al.   CHEMISTRY & BIOLOGY

Antibody–drug conjugates: current status and future directions

(2013) Heidi L. Perez et al.   DRUG DISCOVERY TODAY

Cathepsin B as a cancer target

(2013) Christopher S Gondi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Maturing antibody–drug conjugate pipeline hits 30

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes

(2013) Lee Kim Swee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preparation of unnatural N-to-N and C-to-C protein fusions

(2012) Martin D. Witte et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

(2012) J. Y. Axup et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by sortase A-mediated protein ligation

(2011) Mariusz P. Madej et al.   BIOTECHNOLOGY AND BIOENGINEERING

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

(2011) S. I. Rudnick et al.   CANCER RESEARCH

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Antibody Conjugate Therapeutics: Challenges and Potential

(2011) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

The development of pyrrolobenzodiazepines as antitumour agents

(2011) John A Hartley   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates

(2011) Robert Y. Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase

(2010) Simone Jeger et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Investigational antibody-drug conjugates for hematological malignancies

(2010) Andrew G Polson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monoclonal antibodies — a proven and rapidly expanding therapeutic modality for human diseases

(2010) Zhiqiang An   Protein & Cell

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability

(2009) B ten Cate et al.   LEUKEMIA

A History of Cancer Chemotherapy

(2008) Vincent T. DeVita et al.   CANCER RESEARCH

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH